PTGS2 and glioblastoma: It is tempting to speculate that the lack of significant clinical efficacy of COX-2 inhibition in our animal data and in the clinical experience with patients with glioblastoma may be explained by our finding in situ of increased Wnt activation in the setting of IM therapy.